ArticleTherapeutic advances in medical oncology2026
Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis.
Ping-Chih Hsu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.